Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide

Completed · Phase 2

Conditions studied: Metastatic Progressive Castration-resistant Prostate Cancer

In brief

This study is being conducted to determine the effect of enzalutamide on the androgen signaling pathway in correlation with the anti-tumor effects of enzalutamide to identify potential predictors of response or resistance to therapy.

Key facts

Study ID

NCT01091103

Run by

Pfizer

People needed

60

Starts

2010-02-18

Expected to finish

2013-08-31

Last updated by the study team

2018-10-23

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed prostate cancer
• Presence of metastatic disease to the bone
• Ongoing androgen deprivation therapy

You may not qualify if…

• Severe concurrent disease
• Metastases in the brain

Where it is running

• MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.